Immunotherapy combinations show promise for advanced kidney cancer

A review in JAMA Oncology presents evidence to suggest that first-line immunotherapy combinations could improve efficacy among patients with advanced renal cell carcinoma (RCC).

However, management of immune-related side effects is essential in maximising survival benefit and outcomes.

Read more in Cure here

Share this Post!

Related post